South India Drugs Export And Laboratory Profile
Key Indicators
- Authorised Capital ₹ 3.50 M
as on 23-10-2024
- Paid Up Capital ₹ 3.06 M
as on 23-10-2024
- Company Age 18 Year, 11 Months
- Last Filing with ROC 31 Mar 2023
- Revenue 1.12%
(FY 2023)
- Profit -22.33%
(FY 2023)
- Ebitda -21.11%
(FY 2023)
- Net Worth 9.49%
(FY 2023)
- Total Assets 23.58%
(FY 2023)
About South India Drugs Export And Laboratory
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 3.50 M and a paid-up capital of Rs 3.06 M, as per Ministry of Corporate Affairs (MCA) records.
Sanjeevi Ethirajulu, Geetha Thiagarajan, Elavazhagan Govindasamy, and Two other members serve as directors at the Company.
- CIN/LLPIN
U51397TN2006PTC058620
- Company No.
058620
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
23 Jan 2006
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Chennai
Industry
Company Details
- Location
Kanchipuram, Tamil Nadu, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at South India Drugs Export And Laboratory?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Sanjeevi Ethirajulu  | Managing Director | 23-Jan-2006 | Current |
Board Members(4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Geetha Thiagarajan | Director | 23-Jan-2006 | Current |
| Elavazhagan Govindasamy | Director | 28-Feb-2011 | Current |
| Bhramanantha Jayaraman | Director | 28-Feb-2011 | Current |
| Kuili Jayaraman | Director | 28-Feb-2011 | Current |
Financial Performance of South India Drugs Export And Laboratory.
South India Drugs Export And Laboratory Private Limited, for the financial year ended 2023, experienced modest growth in revenue, with a 1.12% increase. The company also saw a substantial fall in profitability, with a 22.33% decrease in profit. The company's net worth moved up by a moderate rise of 9.49%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of South India Drugs Export And Laboratory?
In 2023, South India Drugs Export And Laboratory had a promoter holding of 62.22% and a public holding of 37.78%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at South India Drugs Export And Laboratory?
Unlock and access historical data on people associated with South India Drugs Export And Laboratory, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of South India Drugs Export And Laboratory, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped South India Drugs Export And Laboratory's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
